Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Exploring professionals' experiences with secure messaging in Dutch outpatient clinics: emerging differences in use frequencies and types across medical specialties.
BMC Med Inform Decis Mak
July 2025
High Select, Hoevelaken, Netherlands.
Background: Secure digital messaging is a two-way communication channel that gained ground in healthcare over the past decade. While a direct channel between patients and providers may support patients, professionals' work pressure makes it imperative that patient-provider communication remains efficient. Thus far, there is little insight into how the use of digital messaging between outpatients and professionals varies across medical specialties and how professionals experience effects on their workload and patient empowerment.
View Article and Find Full Text PDFBackground: In ARIEL3, rucaparib maintenance significantly improved progression-free survival (PFS; primary endpoint) and long-term follow-up (LTFU) outcomes (including PFS2: time to disease progression on subsequent therapy or death) versus placebo in patients with recurrent, platinum-sensitive ovarian cancer. Here we report the final analysis of overall survival (OS; key secondary endpoint), LTFU outcomes, and safety.
Methods: OS and updated LTFU efficacy outcomes were analyzed (data cutoff date: April 4, 2022) across three nested populations (BRCA-mutated, homologous recombination deficient [HRD], and intention to treat [ITT]).
Update on paraproteinemic neuropathy.
Curr Neurol Neurosci Rep
June 2025
University of North Carolina, Chapel Hill, 170 Manning Drive, Chapel Hill, NC, 27599-7025, USA.
Purpose Of Review: This article reviews recent clinical updates and research on the evaluation and management of patients with peripheral neuropathy in association with monoclonal gammopathies.
Recent Findings: Recent studies have elucidated pathogenic mechanisms of IgM paraprotein associated neuropathies, including nodal and paranodal targets and complement mediated processes, suggesting novel therapeutic targets. New chemotherapeutic regimens have improved outcomes and neurotoxic side effect profiles in the treatment of patients with light chain (AL) amyloidosis and POEMS syndrome.
Comparison of Prostate-specific Membrane Antigen Reporting and Data System Version 1.0 versus 2.0 for Prostate Cancer Assessment.
Radiol Imaging Cancer
May 2025
Department of Diagnostic Radiology, Faculty of Human Medicine, Zagazig University, Zagazig, Egypt.
Purpose To assess diagnostic performance and reliability of Prostate-specific Membrane Antigen Reporting and Data System (PSMA-RADS) version 1.0 in evaluating prostate cancer (PCa) and compare it with the updated version (version 2.0).
View Article and Find Full Text PDFCVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes.
Cardiovasc Diabetol
May 2025
Forschergruppe Diabetes e. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany.
The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5-6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA).
View Article and Find Full Text PDF